Laboratorio Reig Jofre SA
MAD:RJF
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.24
3.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Laboratorio Reig Jofre SA
Laboratorio Reig Jofre SA
Long-Term Debt
Laboratorio Reig Jofre SA
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Laboratorio Reig Jofre SA
MAD:RJF
|
Long-Term Debt
€41.7m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Almirall SA
MAD:ALM
|
Long-Term Debt
€346.7m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
1%
|
|
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
Long-Term Debt
€98.1m
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
12%
|
|
|
F
|
Faes Farma SA
MAD:FAE
|
Long-Term Debt
€3.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-17%
|
|
Laboratorio Reig Jofre SA
Glance View
Laboratorio Reig Jofre SA engages in the research, development, manufacture, and trade of pharmaceutical drugs. The company is headquartered in Sant Joan Despi, Barcelona and currently employs 1,152 full-time employees. The company went IPO on 2006-11-07. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The firm also provides nutritional cosmetics, and food supplements, among others. The company operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
See Also
What is Laboratorio Reig Jofre SA's Long-Term Debt?
Long-Term Debt
41.7m
EUR
Based on the financial report for Sep 30, 2024, Laboratorio Reig Jofre SA's Long-Term Debt amounts to 41.7m EUR.
What is Laboratorio Reig Jofre SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
6%
Over the last year, the Long-Term Debt growth was 58%. The average annual Long-Term Debt growth rates for Laboratorio Reig Jofre SA have been -5% over the past three years , 6% over the past five years .
You don't have any saved screeners yet
